May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Comparison of Ahmed Tube Shunt Surgery Alone and Ahmed Combined With Pars Plana Vitrectomy in Neovascular Glaucoma
Author Affiliations & Notes
  • S. J. Lee
    Ophthalmology, Columbia University, New York, New York
  • L. Riansuwan
    Ophthalmology, Columbia University, New York, New York
  • J. C. Tsai
    Ophthalmology, Yale University, New Haven, Connecticut
  • L. A. Al-Aswad
    Ophthalmology, Columbia University, New York, New York
  • Footnotes
    Commercial Relationships S.J. Lee, None; L. Riansuwan, None; J.C. Tsai, None; L.A. Al-Aswad, None.
  • Footnotes
    Support Unrestricted departmental grant from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3963. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. J. Lee, L. Riansuwan, J. C. Tsai, L. A. Al-Aswad; Comparison of Ahmed Tube Shunt Surgery Alone and Ahmed Combined With Pars Plana Vitrectomy in Neovascular Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3963.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To compare and evaluate the outcomes for Ahmed tube shunt surgery (AS) alone versus combined Ahmed tube shunt surgery and pars plana vitrectomy (AS-PPV) in patients with neovascular glaucoma.

Methods:: A retrospective chart review of consecutive patients with neovascular glaucoma who underwent either Ahmed tube shunt surgery (AS) alone or combined Ahmed tube shunt surgery and pars plana vitrectomy (AS-PPV) between June 2001 to June 2006 at Columbia Presbyterian Hospital with a minimum follow-up period of 6 months was performed. Data including age, gender, intraocular pressure (IOP), number of antiglaucoma medications, and complications were recorded. The mean decrease in IOP between the AS and AS-PPV patients were compared using Student’s T-test.

Results:: 11 eyes underwent AS and 7 eyes underwent AS-PPV. 6 (54.5%) were pseudophakic in the AS group and 6 (85.7%) were pseudophakic and 1 (14.3%) aphakic in the AS-PPV group. The mean age in the AS and AS-PPV group was 63.2±21.2 and 74.3±13.1 years, respectively. There was no statistically significant difference in age between the two groups. The mean baseline IOP (AS 41.3±9.3mmHg, AS-PPV 39.0±17.5mmHg) and number of preoperative glaucoma medications (AS 3.9±1.0, AS-PPV 3.7±1.3) were also similar in the two groups. There was no statistically significant difference in the postoperative IOP between the AS and AS-PPV groups at 1 day (17.8±15.6 vs. 14.9±10.2mmHg), 1 week (13.7±12.8 vs. 17.9±19.2mmHg), 1 month (19.1±12.8 vs. 16.3±6.5mmHg), 3 months (18.6±15.8 vs. 16.8±11.1mmHg), and 6 months (19.2±16.8 vs. 14.5±3.1mmHg). The number of postoperative glaucoma medications also did not differ between the two groups. One patient in the AS group had the implant removed due to tube exposure. 4 (36.4%) in the AS group (mean 4.5 days postoperatively, lasting 6.5 days) and 2 (28.6%) in the AS-PPV group (mean 5.5 days postoperatively, lasting 15.5 days) developed choroidal effusion not requiring drainage. One patient in the AS developed a retinal detachment 6 months postoperatively. Three patients were lost to follow-up during the study period.

Conclusions:: Both AS and AS-PPV are equally effective in controlling IOP in patients with neovascular glaucoma in the short term. Larger randomized prospective studies are needed to examine the long term effects of both surgical methods on intraocular pressure control in this subset of patients.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: systems/equipment/techniques • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×